VivoSeq
Ophthalmology

Cystoid Macular Edema

17

Pipeline Programs↗

2

Active Trials↗

7

Companies Involved↗

Cystoid Macular Edema is an emerging landscape with 17 programs across 7 companies. The most active players are Pfizer, Triax, Roche. 5 therapies are approved with 1 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

44/100

Pipeline Velocity

0/100

Mech. Concentration

33/100

Completion Rate

81/100

Attrition Rate

14/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Pfizer logo

Pfizer

1 program

Phase 1T

Triax

1 program

Phase 1Roche logo

Roche

3 programs

Phase 1Teva logo

Teva

1 program

Phase 2AbbVie logo

AbbVie

1 program

Phase 2Novartis logo

Novartis

1 program

Approved

Pipeline

Programs by Phase

Analysis

Modality Breakdown

86%

Small molecule

19 of 22 classified programs — the dominant modality here.

14%ALL OTHERSMonoclonal antibody314%

Small molecule leads; the ring shows all 22 classified programs, each share of the total. Modality classified for 92% of 24 pipeline programs.

Analysis

Trial Status

22

clinical trials

Completed13 · 59%
Unknown status4 · 18%
Withdrawn2 · 9%
Recruiting2 · 9%
Terminated1 · 5%

Clinical Trials

Trial Activity

22 trials

DSAEK/DMEK and Cystoid Macular Edema - the Role for Topical NSAIDs (Nepafenac) (DMEC)
Recruiting·OOslo University Hospital·Phase 4·NCT05072262·300 enrolled
Therapeutic Contact Lens Drug Delivery System (TCL-DDS) in Patients With Recurrent Cystoid Macular Edema
Recruiting·MMassachusetts Eye and Ear Infirmary·Phase 1/2·NCT04225611·6 enrolled
Acute Pseudophakic Cystoid Macular Edema Treatment Trial: Intravitreal Ranibizumab Versus Triamcinolone Acetonide
Completed·—·Phase 1·NCT02294656·4 enrolled
Bromfenac BID Plus Prednisolone Acetate BID Versus Bromfenac BID Plus Prednisolone QID for the Prevention of Cystoid Macular Edema and Retinal Thickening
Completed·CCenter For Excellence In Eye Care·Phase 4·NCT00469781·95 enrolled
Pegaptanib Therapy in Non-Infectious Uveitic Cystoid Macular Edema
Completed·WWake Forest University·N/A·NCT00790803·5 enrolled
The Treatment of Uveitic Cystoid Macular Edema With Topical Interferon Gamma
Completed·National Eye Institute (NEI)·Phase 1·NCT00943982·5 enrolled
Pilot Study of Ranibizumab (Lucentis) for Uveitic Cystoid Macular Edema
Completed·UUniversity of Miami·Phase 1·NCT00826618·6 enrolled
Nerve Growth Factor Eye Drops Treatment in Patients With Retinitis Pigmentosa and Cystoid Macular Edema
Completed·—·Phase 2·NCT02609165·45 enrolled
Randomized Trial of Acetazolamide for Uveitis-Associated Cystoid Macular Edema
Completed·National Eye Institute (NEI)·Phase 2·NCT00000115
Anti-inflammatory Efficacy for Prophylaxis of Cystoid Macular Edema (CME) After Phacoemulsification
Completed·—·Phase 4·NCT02084576·40 enrolled
Treatment of Cystoid Macular Edema in Patients With Retinal Degeneration
Completed·UUniversity of Illinois at Chicago·Phase 4·NCT00716586·44 enrolled
Treatment of Acute Pseudophakic Cystoid Macular Edema: Bromfenac 0.09% Versus Diclofenac Sodium 0.1% Versus Ketorolac Tromethamine 0.5%
Completed·BBp Consulting, Inc·Phase 4·NCT00595543·166 enrolled
Study of Oral Minocycline in Treating Bilateral Cystoid Macular Edema Associated With Retinitis Pigmentosa
Completed·National Eye Institute (NEI)·Phase 1/2·NCT02140164·7 enrolled
Treatment of Post-surgical Cystoid Macular Edema With Topical Steroids Trial (TEMPEST-1)
Completed·JJohns Hopkins University·Phase 2/3·NCT01769352·42 enrolled
Efficacy of Nonsteroidal Anti-Inflammatory Drugs for the Prevention of Cystoid Macular Edema Following Cataract Phacoemulsification
Completed·PPomeranian Medical University Szczecin·Approved·NCT07696104·88 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)